Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Empresa
Empresa
Nuestra historia
Nuestro equipo
Carreras
Socios
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Acceso
Asuntos médicos
Acceso de pacientes
Póngase en contacto con Asuntos Médicos
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Recursos
Recursos
En las noticias
Comunicados de prensa
Recursos para pacientes
Preguntas frecuentes
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Inversores
Inversores
Descripción general del inversor
Información financiera
Eventos
News
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Safety and Immunogenicity of Long HSV-2 Peptides Complexed with rhHsc70 in HSV-2 Seropositive Persons.
Other Articles & Publications
Vaccine
June 2, 2022
,
Wald, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children.
Other Articles & Publications
New England Journal of Medicine
June 2, 2022
,
RTS,S Clinical Trials Partnership, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
A Heat Shock Protein Based Polyvalent Vaccine Targeting HSV-2: CD4(+) and CD8(+) Cellular Immunity and Protective Efficacy.
Other Articles & Publications
Vaccine
June 2, 2022
,
Mo, et al.
No se ha encontrado ningún artículo.
Lea ahora
Descargar ahora
View Article
QS-21 STIMULON™ Adjuvant
Safety and Efficacy of the RTS,S/AS01E Candidate Malaria Vaccine Given With Expanded-Programme-On-Immunisation Vaccines: 19 Month Follow-Up of a Randomised, Open-Label, Phase 2 Trial.